EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial

Norman Aiad iD, Jeanne du Fay de Lavallaz, Michael J Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S Nijjar, Julie A Lahiri, Cindy M Martin, Tamas Alexy, Markus Meyer

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15162 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Norman Aiad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Engdahl Family Chair for Heart Failure Research and in part by the National Institutes of Health, University of Minnesota.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Patients with heart failure with preserved ejection fraction (HFpEF) tend to have low resting and exercise heart rates. Phosphodiesterase-3 (PDE-3) inhibitors improve heart rates, haemodynamics and symptoms in patients with HFpEF. Cilostazol is an oral PDE-3 inhibitor used in peripheral artery disease. This study thought to evaluate the short-term effects of cilostazol on health status, N-terminal brain natriuretic peptide (NT-proBNP) levels and mechanisms of action.

Methods

The effect of cilostazol was evaluated in 23 patients with HFpEF in a randomized placebo controlled multiple crossover trial (CLIP-HFpEF). Participants received placebo or cilostazol for 1 week followed by three crossovers to the alternate assignment at weeks 2, 3 and 4. The primary endpoint was the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score obtained at the end of each treatment period. NT-proBNP was the secondary endpoint. In an exploratory mechanistic analysis, pulmonary artery (PA) pressures and heart rates were followed amongst the five participants with implanted pressure monitors.

Results

Cilostazol improved the KCCQ score by 4.8 points (95% confidence interval, 2.0–7.7, P = 0.003). NT-proBNP levels were 448 (154–1056) pg/mL on placebo and 375 (68–974) pg/mL on cilostazol (P = 0.006). In patients with PA pressure monitors, diastolic pressure was 20.5 (18.7–23.0) mmHg on placebo and 18.0 (17.0–20.0) mmHg on cilostazol, an effect linked to higher heart rates (P < 0.001).

Conclusions

Amongst patients with HFpEF, short-term treatment with cilostazol leads to improvements in health status and NT-proBNP when compared with placebo. These effects are likely conveyed by a heart rate-dependent reduction in cardiac filling pressures. Trial Registration ClinicalTrials.gov Identifier: NCT05126836.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeVentricular Function, LeftHumansCilostazolMaleFemaleCross-Over StudiesAgedPhosphodiesterase 3 InhibitorsNatriuretic Peptide, BrainDouble-Blind MethodPeptide FragmentsMiddle AgedTreatment OutcomeFollow-Up StudiesHeart Rate

Stichwörter der Autor:innen

diastolic functionheart failurepharmacotherapypreserved ejection fraction

Substanzen

CilostazolPhosphodiesterase 3 InhibitorsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Autor:innen und Institutionen

  • Department of Medicine, Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA.
  • Cardiovascular Research Institute Basel, Basel, Switzerland.
  • Department of Surgery, University of Vermont Medical Center, Burlington, Vermont, USA.

ORCID-Profile: Norman Aiad

Förderung

  • Engdahl Family Chair for Heart Failure Research and in part by the National Institutes of Health
  • University of Minnesota

Zitieren

APA

Aiad, N., du Fay de Lavallaz, J., Zhang, M. J., Chaikijurajai, T., Ye, B., Nijjar, P. S., Lahiri, J. A., Martin, C. M., Alexy, T., & Meyer, M. (2025). Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial. ESC Heart Failure. https://doi.org/10.1002/ehf2.15162

Vancouver

Aiad N, du Fay de Lavallaz J, Zhang MJ, Chaikijurajai T, Ye B, Nijjar PS, et al. Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial. ESC Heart Failure. 2025. doi:10.1002/ehf2.15162

BibTeX
@article{Aiad2025,
  author = {Aiad, Norman and du Fay de Lavallaz, Jeanne and Zhang, Michael J and Chaikijurajai, Thanat and Ye, Bo and Nijjar, Prabhjot S and Lahiri, Julie A and Martin, Cindy M and Alexy, Tamas and Meyer, Markus},
  title = {Cilostazol in Patients with Heart Failure and Preserved Ejection Fraction—The CLIP-HFpEF Trial},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15162}
}
Kostenlos starten →